As the Society for Immunotherapy of Cancer (SITC) annual meeting kicks off in Houston, we are honored that SUPLEXA, Alloplex Biotherapeutics’ groundbreaking immunotherapy platform, has been recognized among the Top 100 presentations. This recognition speaks to SUPLEXA’s potential as a new approa...
Date
Categories
Date
Categories
- November 6, 2024
Join Us at SITC 2024 to Discover SUPLEXA’s Breakthrough Potential in Cancer Immunotherapy.
- October 30, 2024
Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough
In a remarkable development for cancer research, patients with advanced-stage cancer have benefited from SUPLEXA, a personalized treatment that trains the patient’s own immune cells to fight cancer. “Cancer often gains the upper hand by suppressing the immune system. Our approach flips the scrip...
- October 24, 2024
Adapting to Immuno-Oncology’s R&D Challenges: Refocusing on Innate Immunity as a “Next Big Thing” in Cancer Immunotherapy
Dr. Borriello was a featured speaker at a live webinar entitled “Adapting to Immuno-Oncology’s R&D Challenges: Refocusing on Innate Immunity as the ‘Next Big Thing’ in Cancer Immunotherapy”. The live webinar, moderated by Lumanity, brought together a diver...
- October 13, 2024
Alloplex’s Groundbreaking Cancer Immunotherapy Selected for SITC24 ‘Top 100’ Presentation
Alloplex Biotherapeutics is pleased to announce that our innovative SUPLEXA immunotherapy platform has been recognized by the Society for Immunotherapy of Cancer (SITC) for its upcoming international conference in Houston, Tx, this November. Two abstracts featuring SUPLEXA have been accepted for pos...
- September 30, 2024
Dr. Borriello to present at live webinar on Immuno-Oncology R&D Challenges
Dr. Borriello will be a featured speaker at an upcoming live webinar entitled “Adapting to Immuno-Oncology’s R&D Challenges: Refocusing on Innate Immunity as the ‘Next Big Thing’ in Cancer Immunotherapy”. The live webinar, being moderated by Lumanity,...
- August 22, 2024
Alloplex Biotherapeutics Welcomes Seasoned Pharmaceutical Executive to its Corporate Board
Alloplex Biotherapeutics Inc., a Boston-based cellular therapeutics company, announced the appointment of Mr. Paul Sowyrda to its Corporate Board this week. Mr. Sowyrda brings over three decades of invaluable experience in the pharmaceutical and biotech industries to Alloplex. His extensive backgrou...
- June 12, 2024
SITC23 Posters with Oral Presentation recording by Alloplex Biotherapeutics Inc’s Founder and Chief Executive Officer, Dr. Frank Borriello.
SITC 2023 Poster 381 and 727 with Audio Commentary by Dr. Borriello
- March 27, 2024
Alloplex set to validate crucial immunotherapy hypothesis and expands corporate structure with advisory panel.
Alloplex Biotherapeutics has identified cancer tumor types responsive to its lead technology platform, SUPLEXA, in a single-agent study.
- September 7, 2023
Two abstracts on Alloplex’s lead technology platform, SUPLEXA, accepted for presentation at SITC23
Dr. Rohit Joshi of CRSA and Alloplex's leadership team will present the latest developments and data from SUPLEXA-101 phase 1 in-human trials in San Diego, CA (November 1 - 5, 2023)
The Society for Immunotherapy of Cancer has accepted two abstracts in relation to the trial of Alloplex’s lead technology platform, SUPLEXA, for presentation at this year’s 38th annual SITC meeting and conference. The posters to be presented by Dr. Rohit Joshi, alongside the Alloplex lea...
- August 22, 2023
Alloplex seeks strategic partners and investor meetings at LSX Leaders Congress (Boston, September 2023)
SUPLEXA cellular therapy, a highly differentiated therapy with exceptionally broad promise, has demonstrated single-agent activity in end-stage solid cancer patients
Alloplex’s founder and CEO, Dr. Frank Borriello, will be attending the upcoming LSX Leaders Congress in Boston on September 13 and 14 at the Hynes Convention Centre. Alloplex is seeking strategic partners and investors to support a de-risked Phase 2 ready clinical stage cellular therapy opport...
- July 25, 2023
Dr. Borriello to present at CHI immuno-oncology summit 2023 in Boston
Dr. Frank Borriello, Alloplex Biotherapeutics Inc’s Founder and CEO, will be speaking at CHI’s 11th Annual Immuno-Ongolocy Summit #IOSummit and chairing the Emerging Cell-Based Therapies session at the Seaport Hotel, Boston, M.A. on August 9. The session starts at 8.55 am and Dr. Borriello’s p...
- June 14, 2023
Alloplex will participate in the CHI’s 7th Annual Immuno-Oncology Summit Europe
Alloplex Biotherapeutics’ Founder and CEO, Dr. Frank Borriello, is a speaker within the Gamma Delta Immunotherapy ‘Exploiting and Enhancing Unique Properties for Cancer Treatment’ track of the CHI Immuno-Oncology Summit Europe, taking place in London from June 20 to 22, 2023. His presentation,...
- May 22, 2023
Dr. Borriello attending Immuno-Oncology Xchange East Coast 2023
Alloplex CEO to participate in round table discussions
Alloplex is pleased to announce its participation in the US East Coast Immuno-Oncology Xchange to be held in Boston on May 23, 2023. Our CEO, Frank Borriello, will be in attendance and participate in a number of round table discussions. Specifically, SUPLEXA therapeutic cells will be discussed in th...
- April 19, 2023
Alloplex to present emerging data from SUPLEXA-101 trial at World Oncology Cell Therapy Congress 2023 in Boston
The presentation will also highlight the development of an unprecedented blood-based pharmacodynamic signature of SUPLEXA activity
We are pleased to announce that Dr. Frank Borriello, Founder and CEO of Alloplex Biotherapeutics, will be presenting at the upcoming World Oncology Cell Therapy Congress, being held in Boston, MA, on April 25 & 26, 2023. The presentation will include emerging data from t...
- December 15, 2022
Alloplex opens third prestigious site for SUPLEXA-101 first-in-class cellular therapy trial in oncology patients
Southern Oncology Clinical Research Unit in Adelaide joins Cancer Research SA, also in Adelaide, and Gallipoli Medical Research Foundation of Brisbane for the Phase 1 trial of Alloplex Biotherapeutics' autologous SUPLEXA cell immunotherapy.
Alloplex Biotherapeutics today announced the opening of the third site in its first-in-human clinical trial of SUPLEXA: Southern Oncology Cancer Research Unit ‘SOCRU’. SUPLEXA therapy is a highly-differentiated, autologous, non-engineered, multi-cellular therapy derived from patient peripheral b...
- August 1, 2022
Independent Data Safety Monitoring Board agrees to continue enrollment in SUPLEXA first-in-human trial
No safety signals or adverse events were observed in the first cohort of three patients with solid cancer who have completed treatment with Alloplex Biotherapeutics Inc.'s SUPLEXA Therapeutic Cells.
On Friday 29 August, an independent Data Safety Monitoring Board ‘DSMB’ unanimously agreed that the trial of Alloplex Biotherapeutics Inc.’s SUPLEXA Therapeutic Cells should to continue to full enrollment.
- July 27, 2022
Dr. Frank Borriello to speak at Gamma Delta T Therapies Summit.
July 28, 2022 in Boston.
Alloplex’s Founder and CEO, Dr. Frank Borriello, will be speaking at the 3rd Gamma Delta T Therapies Summit on Thursday 28th July 2022 at 11am in a session titled “Reviewing the clinical safety and efficacy of gamma delta therapies” on the Response in Solid Tumors of Non-Engineered Autologous...
- April 29, 2022
Alloplex Biotherapeutics announces opening of first clinical trial site
Phase 1 trial of autologous SUPLEXA cell immunotherapy, commences in Adelaide South Australia
Alloplex Biotherapeutics announced today the site opening for its first-in-human clinical trial of SUPLEXA. SUPLEXA therapy is a highly-differentiated, autologous, non-engineered, multi-cellular therapy derived, from patient peripheral blood mononuclear cells. This Phase 1 is a first-in-human, open-...
- April 11, 2022
Alloplex SUPLEXA cells resist immunosuppressive action of two inhibitory cytokines typically found in tumor microenvironment
On April 12, 2022, Jim Lederer, MD, Chief Scientific Officer of Alloplex Biotherapeutics Inc. will present a Poster at the AACR 2022 Annual Meeting in New Orleans, Louisiana: AACR Abstract: IL-10/TGFβ Abstract Control Number: 3599 Title: Interleukin-10 and transforming growth factor-beta do not sup...
- March 29, 2022
Alloplex appoints CLL expert Dr. Jennifer Brown to its scientific advisory board
Dr. Brown, the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts, is internationally known fo...
- February 20, 2022
Alloplex to present Poster at AACR 2022
Alloplex’s Abstract (3599) ‘Interleukin-10 and transforming growth factor-beta do not suppress tumor killing activity of PBMC-derived SUPLEXA cells’ has been accepted by AACR and is scheduled for presentation in a Poster session at the 2022 Annual Meeting. We look forward to attending this yea...
- January 17, 2022
Human Research Ethics Committee (HREC) in Australia approves the start of the first SUPLEXA Phase 1 Clinical Trial
Alloplex Biotherapeutics, Inc. (‘Alloplex’) – a private cellular therapeutics company dedicated to developing and commercializing a global first-in-class cellular therapeutic in oncology – today announced that the Human Research Ethics Committee (HREC) in Australia has approved the clinical...
- December 15, 2021
Hackensack Meridian Health’s Bear’s Den supports company developing novel way to ‘train’ patients’ own white blood cells
Alloplex Biotherapeutic and Hackensack Meridian Health announce equity investment.
Hackensack Meridian Health, New Jersey’s largest and most comprehensive health network, is proud to announce its support of the clinical development of a highly-differentiated immuno-oncology platform by Boston-based Alloplex Biotherapeutics, Inc.
- December 8, 2021
Alloplex appoints Dr. Andre Goy to its scientific advisory board
Dr. Goy is Physician in Chief of Hackensack Meridian Health Oncology Care Transformation Service; Chairman & Chief Physician Officer of John Theurer Cancer Center (JTCC) at Hackensack University Medical Center; Lydia Pfund Chair for Lymphoma; Academic Chairman Oncology at Hackensack Meridian School...
- November 15, 2021
Alloplex presents poster describing novel tumor-killing cells at SITC 2021 Conference
Non-engineered SUPLEXA cells demonstrate potent activity against patient-derived cancer organoids in vitro.
Today Alloplex Biotherapeutics released details of its abstract entitled Potent Tumor Organoid Infiltration and Killing by PBMC-Derived Effector Cells presented at SITC 2021. Alloplex’s abstract shows that the organization can generate tumor-killing cells from PBMCs using a clinical grade manufact...
- November 1, 2021
Alloplex forms corporate board
Appoints two members: Dr. Sung-Wuk Kim and TaeOh ‘Jared’ Chung.
Alloplex Biotherapeutics Inc. announced the formation of a Corporate Board today: at a pivotal juncture in the organization’s development as it is poised to embark on its first-in-human clinical trial.
- September 29, 2021
A tribute to Dr. Martin ‘Mac’ Cheever
It is with great sadness that we learned this week that Dr. Mac Cheever died of complications from what was a planned cardiac surgery earlier this year. Mac’s achievements over 40 years at the Fred Hutchinson Cancer Research Center were well known and admired across the immunology community.
- June 28, 2021
Alloplex to participate at Roth Capital Partners Healthcare Private Company Forum
Dr. Frank Borriello will be participating in Roth’s Capital Partners’ Virtual Healthcare Private Company Forum on June 28 as part of Cancer Panel 2: entitled Natural Killer Cell Approaches to Eradicate Tumors where he will be highlighting the differentiation of the Alloplex approach in the oncol...
- March 22, 2021
Alloplex Biotherapeutics will attend the Innate Killer Cell Conference
The Innate Killer Cell Conference on March 24-25, 2021 held by Hanson Wade.
- August 3, 2020
Alloplex Biotherapeutics to Present at the LifeSci Partners Summer Symposium
Alloplex CEO Frank Borriello MD, PhD will be presenting a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners on August 4 and 5, 2020.
- May 4, 2020
Alloplex Biotherapeutics Announces Participation in the Cancer Progress Meeting
Alloplex Biotherapeutics announces its participation in the Cancer Progress Meeting to be held virtually on May 5-6, 2020.
- May 1, 2020
Alloplex Biotherapeutics Announces Addition to its Scientific Advisory Board
Alloplex Biotherapeutics is pleased to announce the addition of Dr. Robin Robinson to our scientific advisory board.